10-Q: TransCode Therapeutics Reports Third Quarter 2024 Results Amidst Financial and Nasdaq Challenges

TransCode Therapeutics' Q3 2024 report reveals ongoing losses, a cash runway into late 2024, and challenges with Nasdaq listing compliance.

Summary

• TransCode Therapeutics reported a net loss of $10.8 million for the nine months ended September 30, 2024, and a net loss of $2.3 million for the three months ended September 30, 2024.
• The company's cash balance stood at approximately $1.9 million as of September 30, 2024, which is expected to fund operations into late 2024.
• Research and development expenses decreased to $6.1 million for the nine months ended September 30, 2024, compared to $8.9 million for the same period in 2023.
• General and administrative expenses also decreased to $4.5 million for the nine months ended September 30, 2024, from $6.4 million in the same period of 2023.
• The company is facing potential delisting from the Nasdaq Capital Market due to non-compliance with listing rules, and has been granted an extension to regain compliance.
• TransCode has commenced a Phase 1 clinical trial for its lead therapeutic candidate, TTX-MC138, with the first cohort receiving the lowest therapeutic dose level.
• The company received a second NIH Award of $1,999,972 to support clinical trial activities over two years.
• The company has an accumulated deficit of approximately $57.3 million as of September 30, 2024.

Sentiment

Score: 3

Explanation: The document presents a challenging financial situation with significant risks, including a short cash runway, potential delisting, and ongoing losses. While there are some positive developments, such as the commencement of a Phase 1 trial and a new NIH award, the overall sentiment is negative due to the financial and listing concerns.

Positives

• The company has commenced a Phase 1 clinical trial for its lead therapeutic candidate, TTX-MC138.
• TransCode received a second NIH Award of $1,999,972 to support clinical trial activities.
• The company has reduced both research and development and general and administrative expenses compared to the previous year.
• Preliminary data from the Phase 0 trial showed that radioactivity consistent with accumulation of TTX-MC138 was detected in the regions of the metastatic lesions.
• The company has been granted a formal extension to regain compliance with Nasdaq listing rules.

Negatives

• The company has incurred significant operating losses and negative cash flows from operations.
• The company's cash reserves are expected to last only until late 2024.
• TransCode is facing potential delisting from the Nasdaq Capital Market due to non-compliance with listing rules.
• The company has an accumulated deficit of approximately $57.3 million.
• The company's disclosure controls and procedures were not effective as of September 30, 2024.

Risks

• The company's ability to continue as a going concern is in doubt without additional capital.
• There is a risk of delisting from the Nasdaq Capital Market, which could limit access to capital.
• The company may need to restructure its liabilities if it cannot raise additional capital.
• The company's product development is subject to numerous risks and uncertainties.
• The company's financial results could be materially and adversely affected by global economic and political developments.
• The company has identified material weaknesses in its internal control over financial reporting.

Future Outlook

The company plans to continue development of its lead therapeutic candidate and other candidates, and explore strategic partnerships. Management believes that current cash is sufficient to fund operations and capital requirements into the fourth quarter 2024, but does not believe that existing cash will be sufficient to fund requirements for a full 12 months from the date of these financial statements. The company will require additional capital to support continued operations.

Management Comments

• Management believes that current cash is sufficient to fund operations and capital requirements into the fourth quarter 2024.
• Management does not believe that existing cash will be sufficient to fund requirements for a full 12 months from the date of these financial statements.
• The company plans to continue development of its lead therapeutic candidate and other candidates, and explore strategic partnerships.

Industry Context

The company is operating in the competitive biopharmaceutical industry, facing challenges common to early-stage companies, including the need for substantial capital, regulatory hurdles, and clinical trial risks. The company's focus on targeted RNA therapeutics aligns with a growing trend in the industry, but it faces competition from other companies developing similar technologies.

Comparison to Industry Standards

• TransCode's cash runway is shorter than many comparable biotech companies, which typically aim for at least 12 months of funding.
• The company's R&D spending is lower than some peers, reflecting its current stage of development and financial constraints.
• The company's accumulated deficit is significant, which is not uncommon for early-stage biotech companies but highlights the need for successful clinical trials and commercialization.
• The risk of Nasdaq delisting is a significant concern, as it could impact the company's ability to raise capital and attract investors. Comparible companies such as Avenue Therapeutics, Inc. and Cyclacel Pharmaceuticals, Inc. have faced similar challenges.
• The company's Phase 1 clinical trial is a key milestone, but the success of the trial is uncertain and will be closely watched by investors. Comparible companies such as BioLineRx Ltd. and Veru Inc. are also in similar stages of clinical development.

Management Changes

Legal Proceedings

• The company is disputing a claim by an investment bank for fees.

Stakeholder Impact

• Shareholders face the risk of significant dilution or loss of investment due to potential capital raises or restructuring.
• Employees may be affected by potential cost reduction strategies, including layoffs.
• Customers (potential patients) may be impacted by delays or termination of development programs.
• Suppliers and creditors face the risk of non-payment or restructuring of liabilities.

Next Steps

• The company will continue to advance the Phase 1 clinical trial for TTX-MC138.
• The company will seek to regain compliance with Nasdaq listing rules.
• The company will explore strategic partnerships.
• The company will seek additional funding through equity, debt, or grants.

Key Dates

Keywords

TransCode Therapeutics, TTX-MC138, clinical trial, Nasdaq, delisting, financial results, biopharmaceutical, oncology, research and development, capital raise, NIH Award, going concern